Regenxbio - Public Comps and Valuation Multiples

Regenxbio Overview

About Regenxbio

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Founded

2008

HQ

Employees

353

Website

regenxbio.com

Sectors

Drug Development & Therapeutics
Biopharmaceuticals
BioTech

Financials

LTM Revenue $189M

LTM EBITDA -$103M

EV

$219M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Regenxbio Financials

As of August 2025, Regenxbio reported last 12-month revenue of $189M and EBITDA of -$103M.

In the same period, Regenxbio generated $159M in LTM gross profit and -$152M in net income.

See Regenxbio valuation multiples based on analyst estimates

Regenxbio P&L

In the most recent fiscal year, Regenxbio reported revenue of $83.3M and EBITDA of -$198M.

Regenxbio expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Regenxbio valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$189M	XXX	$83.3M	XXX	XXX	XXX
Gross Profit	$159M	XXX	$49.8M	XXX	XXX	XXX
Gross Margin	84%	XXX	60%	XXX	XXX	XXX
EBITDA	-$103M	XXX	-$198M	XXX	XXX	XXX
EBITDA Margin	-54%	XXX	-238%	XXX	XXX	XXX
EBIT	-$141M	XXX	-$231M	XXX	XXX	XXX
EBIT Margin	-74%	XXX	-278%	XXX	XXX	XXX
Net Profit	-$152M	XXX	-$227M	XXX	XXX	XXX
Net Margin	-80%	XXX	-273%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Regenxbio including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $189M. EBITDA for the last twelve months was -$103M. In the most recent fiscal year, Regenxbio achieved $83.3M in revenue and -$198M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$189M	Analyst estimates available to subscribers	$83.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$159M	Analyst estimates available to subscribers	$49.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	84.3% gross margin	Analyst estimates available to subscribers	59.7% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$103M	Analyst estimates available to subscribers	-$198M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-54.4% EBITDA margin	Analyst estimates available to subscribers	-237.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$141M	Analyst estimates available to subscribers	-$231M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-74.4% EBIT margin	Analyst estimates available to subscribers	-277.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$152M	Analyst estimates available to subscribers	-$227M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-80.4% net profit margin	Analyst estimates available to subscribers	-272.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Regenxbio

This financial data table provides comprehensive performance metrics for Regenxbio, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Regenxbio generated $189M in revenue over the last twelve months.
The company achieved -$103M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $159M.
Net income over the last twelve months reached -$152M.

Fiscal Year Performance

In the most recent fiscal year, Regenxbio reported $83.3M in total revenue.
Fiscal year EBITDA was -$198M.
The company maintained a gross profit margin of 59.7% in the most recent fiscal year.
EBITDA margin for the fiscal year was -237.9%.
Net profit margin reached -272.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Regenxbio. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Regenxbio Stock Performance

Regenxbio has current market cap of $465M, and EV of $219M.

Market Cap Evolution

Regenxbio Stock Data

As of September 12, 2025, Regenxbio's stock price is $9.

See Regenxbio trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$219M	$465M	XXX	XXX	XXX	XXX	$-2.91

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Regenxbio Valuation Multiples

Regenxbio's trades at 2.6x EV/Revenue multiple, and -1.1x EV/EBITDA.

See valuation multiples for Regenxbio and 15K+ public comps

Regenxbio Financial Valuation Multiples

As of September 12, 2025, Regenxbio has market cap of $465M and EV of $219M.

Equity research analysts estimate Regenxbio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Regenxbio has a P/E ratio of -3.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$465M	XXX	$465M	XXX	XXX	XXX
EV (current)	$219M	XXX	$219M	XXX	XXX	XXX
EV/Revenue	1.2x	XXX	2.6x	XXX	XXX	XXX
EV/EBITDA	-2.1x	XXX	-1.1x	XXX	XXX	XXX
EV/EBIT	-1.6x	XXX	-0.9x	XXX	XXX	XXX
EV/Gross Profit	1.4x	XXX	n/a	XXX	XXX	XXX
P/E	-3.1x	XXX	-2.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-1.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Regenxbio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Regenxbio Margins & Growth Rates

Regenxbio's last 12 month revenue growth is 38%

Regenxbio's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.

Regenxbio's rule of 40 is -228% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Regenxbio's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Regenxbio and other 15K+ public comps

Regenxbio Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	38%	XXX	81%	XXX	XXX	XXX
EBITDA Margin	-54%	XXX	-238%	XXX	XXX	XXX
EBITDA Growth	-13%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-228%	XXX	-200%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	40%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.8M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	250%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	337%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial